Neos Therapeutics Inc. (NASDAQ:NEOS)‘s stock had its “buy” rating reiterated by research analysts at BMO Capital Markets in a report issued on Tuesday. They currently have a $15.00 target price on the stock. BMO Capital Markets’ target price indicates a potential upside of 98.68% from the company’s previous close.

Neos Therapeutics (NASDAQ:NEOS) opened at 7.55 on Tuesday. The stock’s 50 day moving average is $7.59 and its 200-day moving average is $9.11. Neos Therapeutics has a 12 month low of $6.33 and a 12 month high of $22.02. The firm’s market cap is $121.33 million.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by $0.49. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. On average, analysts anticipate that Neos Therapeutics will post ($5.38) earnings per share for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/neos-therapeutics-inc-neos-given-buy-rating-at-bmo-capital-markets.html

In other Neos Therapeutics news, CFO Richard I. Eisenstadt purchased 3,710 shares of the stock in a transaction on Thursday, August 25th. The shares were purchased at an average cost of $6.82 per share, for a total transaction of $25,302.20. Following the purchase, the chief financial officer now owns 3,710 shares of the company’s stock, valued at $25,302.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.85% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. Perceptive Advisors LLC raised its stake in shares of Neos Therapeutics by 526.9% in the second quarter. Perceptive Advisors LLC now owns 626,876 shares of the company’s stock valued at $4,611,000 after buying an additional 526,876 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Neos Therapeutics by 58.5% in the second quarter. BlackRock Fund Advisors now owns 566,112 shares of the company’s stock valued at $5,254,000 after buying an additional 209,054 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Neos Therapeutics by 12.3% in the second quarter. Vanguard Group Inc. now owns 293,989 shares of the company’s stock valued at $2,729,000 after buying an additional 32,266 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Neos Therapeutics by 52.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 172,536 shares of the company’s stock valued at $1,601,000 after buying an additional 59,533 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Neos Therapeutics by 61.2% in the second quarter. State Street Corp now owns 104,530 shares of the company’s stock valued at $972,000 after buying an additional 39,705 shares during the last quarter. Hedge funds and other institutional investors own 37.73% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

5 Day Chart for NASDAQ:NEOS

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.